| Michael D Keppen, MD | |
|
1309 W 17th St, Ste 101, Sioux Falls, SD 57104-8805 | |
| (605) 328-8000 | |
| (605) 328-8001 |
| Full Name | Michael D Keppen |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 46 Years |
| Location | 1309 W 17th St, Sioux Falls, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881690592 | NPI | - | NPPES |
| 6002232 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 3341 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Aberdeen | Aberdeen, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Health Network | 6800707100 | 272 |
News Archive
Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.
Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
Vaccinating people against gum disease will be the aim of world-first Melbourne research that today receives a $21.2 million boost from the Federal Government.
› Verified 9 days ago
| Entity Name | Sanford Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396764254 PECOS PAC ID: 0244143824 Enrollment ID: O20031110000532 |
News Archive
Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.
Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
Vaccinating people against gum disease will be the aim of world-first Melbourne research that today receives a $21.2 million boost from the Federal Government.
› Verified 9 days ago
| Entity Name | Sanford Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790721280 PECOS PAC ID: 6800707100 Enrollment ID: O20031111000266 |
News Archive
Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.
Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
Vaccinating people against gum disease will be the aim of world-first Melbourne research that today receives a $21.2 million boost from the Federal Government.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael D Keppen, MD Po Box 5074, Sioux Falls, SD 57117-5074 Ph: (605) 328-9556 | Michael D Keppen, MD 1309 W 17th St, Ste 101, Sioux Falls, SD 57104-8805 Ph: (605) 328-8000 |
News Archive
Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.
Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
Vaccinating people against gum disease will be the aim of world-first Melbourne research that today receives a $21.2 million boost from the Federal Government.
› Verified 9 days ago
Jaroslaw Mateuszczyk, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1205 S Grange Ave Ste 201, Sioux Falls, SD 57105 Phone: 605-328-8188 | |
Aaron Burkhardt, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6100 S Louise Ave Ste 1120, Sioux Falls, SD 57108 Phone: 605-504-1700 | |
Curtis Blake Rexroth, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1325 S Cliff Ave, Sioux Falls, SD 57105 Phone: 605-322-8000 | |
Vinod Parameswaran, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1000 E. 23rd St., Ste. 200, Sioux Falls, SD 57105 Phone: 605-322-3035 Fax: 605-322-3036 | |
Lloyd E Solberg, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1301 W 18th St, Sioux Falls, SD 57105 Phone: 605-312-2200 | |
Ismail Omran, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1205 S Grange Ave Ste 201, Sioux Falls, SD 57105 Phone: 605-238-8100 | |
Francine Vanessa Arneson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 911 E. 20th St., Ste. 509, Sioux Falls, SD 57105 Phone: 605-322-8993 |